You are here

Article Text

Article menu

Download PDFPDF

Idiopathic pulmonary fibrosis treatment update
M28 Deferring treatment with pirfenidone results in loss of lung function that is not recovered by later treatment initiation
Free
  1. T Maher1,
  2. S Jouneau2,
  3. L Morrison3,
  4. D Lederer4,
  5. M Molina-Molina5,
  6. K-U Kirchgaessler6,
  7. F Gilberg6,
  8. J Axmann6,
  9. U Petzinger7,
  10. E Bendstrup8
  1. 1Royal Brompton Hospital and Imperial College London, London, UK
  2. 2Hôpital Pontchaillou, IRSET UMR 1085, Université de Rennes 1, Rennes, France
  3. 3Department of Medicine, Duke University, Durham, NC, US
  4. 4Columbia University Medical Centre, New York, NY, US
  5. 5University Hospital of Bellvitge, Institut d’Investigacions Biomèdiques de Bellvitge, Barcelona, and Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain
  6. 6F. Hoffmann-La Roche Ltd., Basel, Switzerland
  7. 7Accovion GmbH, Eschborn, Germany
  8. 8Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus, Denmark

Abstract

Introduction Idiopathic pulmonary fibrosis (IPF) is characterised by a progressive loss of lung function. Intervention with an anti-fibrotic, such as pirfenidone, as early as possible in the disease course may be the most appropriate strategy to preserve lung capacity.1 In this analysis, data from the pivotal CAPACITY (004/006; NCT00287716/NCT00287729) trials and subsequent RECAP (012; NCT00662038) rollover trial were used to investigate the impact of deferring pirfenidone treatment on annual decline in lung function (forced vital capacity [FVC]) in patients with IPF.

Methods The annual rate of lung function (FVC; mL) decline was calculated for all treated patients who completed CAPACITY and RECAP. Weeks 0–120 included all patients randomised in CAPACITY to pirfenidone 2,403 mg/day or placebo. Weeks 72–120 included data for the transition period, when patients either continued pirfenidone or switched to pirfenidone in RECAP. After Week 120, only data for patients in RECAP were included. Patients randomised to pirfenidone in CAPACITY were compared with those who received placebo in CAPACITY before initiating pirfenidone in RECAP.

Results From Week 0 to 120, the annual rate of lung function decline (FVC) was −142.0 mL (n=345) in patients who received pirfenidone in CAPACITY and −182.3 mL (n=347) in those who received placebo. During the transition period (Weeks 72–120), these values were −155.2 mL (n=236) and −151.9 mL (n=249) in patients who continued and switched to pirfenidone, respectively. In RECAP (≥Week 120), the annual rate of lung function decline in patients who received pirfenidone in both trials was −145.3 mL (n=219) and −140.9 mL (n=218) in those who switched from placebo to pirfenidone.

Conclusions These data show that loss of lung function during CAPACITY was not recovered during RECAP. Therefore, failure to initiate pirfenidone treatment in IPF as early as possible may lead to an irrecoverable loss of lung volume during the period without treatment.

Funding F. Hoffmann-La Roche, Ltd./Genentech, Inc.

Reference

  1. . Albera Cet al. Eur Respir J2016;48:843–851.

Abstract M28 Figure 1
Abstract M28 Figure 1

Annual rate of decline in lung volume in CAPACITY and RECAP.

https://doi.org/10.1136/thoraxjnl-2017-210983.450

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.